Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.
Read, watch & listen to some of the latest thought leadership from our Community.
Women Leaders in an AI Era: Navigating Opportunity and Change
AI has swiftly become a defining force in business life, reshaping how organisations operate, compete and grow. This report by AlixPartners explores how women in senior leadership are responding to business disruption, ...
Unlocking Volume Growth - Retail's Defining Challenge
Growth within retail is proving harder than ever before, with growing geopolitical and economic uncertainty hitting consumer confidence, impacting inflation and disrupting supply chains. This report by AlixPartners ...
IPEM Allocation and Fundraising Trend Report 2027
The private markets industry is entering a new investment cycle, with LPs increasingly focused on diversification, alpha generation and demonstrable value creation, as return expectations come under pressure. This repor...
Displaying 1 to 3 of 211
We use cookies to improve your experience. By using our site, you agree to our use of cookies.
